Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Makov Efrat

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/1/2020

3. Issuer Name and Ticker or Trading Symbol

Anchiano Therapeutics Ltd. [ANCN]

(Last) (First) (Middle)

C/O ANCHIANO THERAPEUTICS LTD., 5 KIRYAT HAMADA ST., P.O. BOX 45032

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

JERUSALEM, L3 9777401

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee stock options	⁽¹⁾	9/19/2028	Ordinary Shares	353	$4.11 ⁽³⁾	D
Employee stock options	⁽²⁾	7/2/2029	Ordinary Shares	55000	$1.03	D

Explanation of Responses:
(1)	1/4 of the options vest one year following the vesting commencement date of September 20, 2018, and 1/16 at the end of each calendar quarter thereafter, until fully vested.
(2)	1/3 of the options vest one year following the vesting commencement date of July 3, 2019, and 1/12 at the end of each calendar quarter thereafter, until fully vested.
(3)	The exercise price was converted from New Israeli Shekel ("NIS") 14.73 using the Bank of Israel representative rate known on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Makov Efrat C/O ANCHIANO THERAPEUTICS LTD. 5 KIRYAT HAMADA ST., P.O. BOX 45032 JERUSALEM, L3 9777401	X